| Name | Title | Contact Details |
|---|
Portola Pharmaceuticals is dedicated to developing and commercializing therapies that transform patient lives and advance patient care by changing treatment paradigms in thrombosis and other hematologic diseases. Our two lead assets are Bevyxxa® (betrixaban), and andexanet alfa. In addition, cerdulatinib is our investigational Syk/JAK inhibitor to treat hematologic cancers. These compounds come from our own internal research efforts and represent important advances to address significant unmet needs. We are employing novel strategies that may increase the likelihood of clinical, regulatory and commercial success of our potentially lifesaving therapies.
National Surgical Adjuvant Breast and Bowel is a Pittsburgh, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
WESTLAKE Financial Group, INC is a Buffalo Grove, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Innovation Place is a Saskatoon, SK-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Finnzymes, Inc. is a Woburn, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.